SuperworthGrace Therapeutics shares outstanding GRCE
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 17.3M
- On a year earlier
- +8.4%
- more shares
Grace Therapeutics had 17.3M diluted shares outstanding on average in Q1 FY27, the quarter to Jun 30, 2026.
That is 8.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2026 | 17.3M | +25% |
| FY2025 | 13.9M | +20% |
| FY2024 | 11.5M | +54% |
| FY2023 | 7.5M | −36% |
| FY2022 | 11.8M | +198% |
| FY2021 | 4M | +111% |
| FY2020 | 1.9M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q1 FY27 | 17.3M | +8% | |
| Q4 FY26 | 17.3M | +25% | |
| Q3 FY26 | 16.9M | +47% | |
| Q2 FY26 | 15.9M | +38% | |
| Q1 FY26 | 15.9M | +46% | |
| Q4 FY25 | 13.9M | +20% | |
| Q3 FY25 | 11.5M | −0% | |
| Q2 FY25 | 11.5M | +52% | |
| Q1 FY25 | 10.9M | +47% | |
| Q4 FY24 | 11.5M | +54% | |
| Q3 FY24 | 11.5M | +55% | |
| Q2 FY24 | 7.6M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Grace Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.